1,3-dimethylamylamine
Small moleculeexperimental
Methylhexanamine is an indirect sympathomimetic drug invented and developed by Eli Lilly and Company and marketed as an inhaled nasal decongestant from 1948 until it was voluntarily withdrawn from the market in the 1980s. — Wikipedia
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2012 (NCT01765933)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMethylhexanamine ↗
Also known as
- 1,3-dimethylamylamine
- 1,3-dimethylamylamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01765933 | N/A | Apr 1, 2012 | University of Memphis, University of Tennessee, USP Labs, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Memphis | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Tennessee | Academic/Hospital | 1 | 0 | 1 | 2012 |
| USP Labs, Inc. | For profit | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1